HIF1A and Miyoshi myopathy: Despite advances in chemotherapy and immunotherapy, MM remains largely incurable, prompting ongoing research into biological markers for more personalized treatment.12,19,20 Hypoxia was shown to reduce the responsiveness of MM cells to cisplatin while increasing their invasiveness and the synthesis of hypoxia-inducible factor 1 (HIF-1), suggesting that HIF-1 could represent a significant target for potential new therapeutic approaches in MM.21